Biochemotherapy vs chemotherapy alone
Toxicity (≥ G3) · people with cutaneous melanoma
Biochemotherapy leads to higher toxicity (≥ G3) compared with chemotherapy (high certainty).
1 finding from 1 review
- RR 1.35 [1.14, 1.61]631 participantsHigh
Findings
What do systematic reviews say?
7 questions · 7 findings · 1 reviews · Skin
No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 3 · 42.9%Moderate 3 · 42.9%High 1 · 14.3%
Polychemotherapy vs chemotherapy alone
Toxicity (≥ G3) · people with cutaneous melanoma
Polychemotherapy probably leads to higher toxicity (≥ G3) compared with chemotherapy (moderate certainty).
1 finding from 1 review
- RR 1.97 [1.44, 2.71]390 participantsModerate
Anti‐angiogenic drugs plus chemotherapy vs chemotherapy alone
Toxicity (≥ G3) · people with cutaneous melanoma
Anti‐angiogenic drugs plus chemotherapy showed no clear difference in toxicity (≥ G3) compared with chemotherapy (low certainty).
1 finding from 1 review
- RR 0.68 [0.09, 5.32]324 participantsLow
Anti‐CTLA4 monoclonal antibodies plus chemotherapy vs chemotherapy alone
Toxicity (≥ G3) · people with cutaneous melanoma
Anti‐CTLA4 monoclonal antibodies plus chemotherapy probably leads to higher toxicity (≥ G3) compared with chemotherapy (moderate certainty).
1 finding from 1 review
- RR 1.69 [1.19, 2.42]1142 participantsModerate
BRAF inhibitors vs chemotherapy alone
Toxicity (≥ G3) · people with cutaneous melanoma
BRAF inhibitors showed no clear difference in toxicity (≥ G3) compared with chemotherapy (low certainty).
1 finding from 1 review
- RR 1.27 [0.48, 3.33]408 participantsLow
MEK inhibitors vs chemotherapy alone
Toxicity (≥ G3) · people with cutaneous melanoma
MEK inhibitors probably leads to higher toxicity (≥ G3) compared with chemotherapy (moderate certainty).
1 finding from 1 review
- RR 1.61 [1.08, 2.41]91 participantsModerate
Anti‐PD1 monoclonal antibodies vs chemotherapy alone
Toxicity (≥ G3) · people with cutaneous melanoma
1 finding from 1 review
- 0.55 [0.31, 0.97]1360 participantsLow